ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 1.99 USD 2.58% Market Closed
Market Cap: 192.4m USD
Have any thoughts about
ADC Therapeutics SA?
Write Note

Intrinsic Value

ADCT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ADCT stock under the Base Case scenario is 5.3 USD. Compared to the current market price of 1.99 USD, ADC Therapeutics SA is Undervalued by 62%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ADCT Intrinsic Value
5.3 USD
Undervaluation 62%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ADC Therapeutics SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ADCT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ADCT?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
ADC Therapeutics SA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about ADC Therapeutics SA

Provide an overview of the primary business activities
of ADC Therapeutics SA.

What unique competitive advantages
does ADC Therapeutics SA hold over its rivals?

What risks and challenges
does ADC Therapeutics SA face in the near future?

Has there been any significant insider trading activity
in ADC Therapeutics SA recently?

Summarize the latest earnings call
of ADC Therapeutics SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ADC Therapeutics SA.

Provide P/S
for ADC Therapeutics SA.

Provide P/E
for ADC Therapeutics SA.

Provide P/OCF
for ADC Therapeutics SA.

Provide P/FCFE
for ADC Therapeutics SA.

Provide P/B
for ADC Therapeutics SA.

Provide EV/S
for ADC Therapeutics SA.

Provide EV/GP
for ADC Therapeutics SA.

Provide EV/EBITDA
for ADC Therapeutics SA.

Provide EV/EBIT
for ADC Therapeutics SA.

Provide EV/OCF
for ADC Therapeutics SA.

Provide EV/FCFF
for ADC Therapeutics SA.

Provide EV/IC
for ADC Therapeutics SA.

Show me price targets
for ADC Therapeutics SA made by professional analysts.

What are the Revenue projections
for ADC Therapeutics SA?

How accurate were the past Revenue estimates
for ADC Therapeutics SA?

What are the Net Income projections
for ADC Therapeutics SA?

How accurate were the past Net Income estimates
for ADC Therapeutics SA?

What are the EPS projections
for ADC Therapeutics SA?

How accurate were the past EPS estimates
for ADC Therapeutics SA?

What are the EBIT projections
for ADC Therapeutics SA?

How accurate were the past EBIT estimates
for ADC Therapeutics SA?

Compare the revenue forecasts
for ADC Therapeutics SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ADC Therapeutics SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ADC Therapeutics SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of ADC Therapeutics SA compared to its peers.

Compare the P/E ratios
of ADC Therapeutics SA against its peers.

Discuss the investment returns and shareholder value creation
comparing ADC Therapeutics SA with its peers.

Analyze the financial leverage
of ADC Therapeutics SA compared to its main competitors.

Show all profitability ratios
for ADC Therapeutics SA.

Provide ROE
for ADC Therapeutics SA.

Provide ROA
for ADC Therapeutics SA.

Provide ROIC
for ADC Therapeutics SA.

Provide ROCE
for ADC Therapeutics SA.

Provide Gross Margin
for ADC Therapeutics SA.

Provide Operating Margin
for ADC Therapeutics SA.

Provide Net Margin
for ADC Therapeutics SA.

Provide FCF Margin
for ADC Therapeutics SA.

Show all solvency ratios
for ADC Therapeutics SA.

Provide D/E Ratio
for ADC Therapeutics SA.

Provide D/A Ratio
for ADC Therapeutics SA.

Provide Interest Coverage Ratio
for ADC Therapeutics SA.

Provide Altman Z-Score Ratio
for ADC Therapeutics SA.

Provide Quick Ratio
for ADC Therapeutics SA.

Provide Current Ratio
for ADC Therapeutics SA.

Provide Cash Ratio
for ADC Therapeutics SA.

What is the historical Revenue growth
over the last 5 years for ADC Therapeutics SA?

What is the historical Net Income growth
over the last 5 years for ADC Therapeutics SA?

What is the current Free Cash Flow
of ADC Therapeutics SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for ADC Therapeutics SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ADC Therapeutics SA

Current Assets 333m
Cash & Short-Term Investments 274.3m
Receivables 24m
Other Current Assets 34.7m
Non-Current Assets 16.1m
PP&E 14.9m
Other Non-Current Assets 1.2m
Current Liabilities 67.7m
Accounts Payable 14.4m
Accrued Liabilities 33.4m
Other Current Liabilities 19.9m
Non-Current Liabilities 453.3m
Long-Term Debt 436.8m
Other Non-Current Liabilities 16.5m
Efficiency

Earnings Waterfall
ADC Therapeutics SA

Revenue
123.5m USD
Cost of Revenue
-7.1m USD
Gross Profit
116.4m USD
Operating Expenses
-380.6m USD
Operating Income
-264.2m USD
Other Expenses
-103m USD
Net Income
-367.2m USD

Free Cash Flow Analysis
ADC Therapeutics SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ADCT Profitability Score
Profitability Due Diligence

ADC Therapeutics SA's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional ROE
Positive 3-Year Average ROE
49/100
Profitability
Score

ADC Therapeutics SA's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

ADCT Solvency Score
Solvency Due Diligence

ADC Therapeutics SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Positive Net Debt
Long-Term Solvency
40/100
Solvency
Score

ADC Therapeutics SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ADCT Price Targets Summary
ADC Therapeutics SA

Wall Street analysts forecast ADCT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADCT is 9.18 USD with a low forecast of 8.08 USD and a high forecast of 10.5 USD.

Lowest
Price Target
8.08 USD
306% Upside
Average
Price Target
9.18 USD
361% Upside
Highest
Price Target
10.5 USD
428% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ADCT?

Click here to dive deeper.

Dividends

ADC Therapeutics SA
does not pay dividends
Shareholder Yield

Current shareholder yield for ADCT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ADCT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

ADC Therapeutics SA Logo
ADC Therapeutics SA

Country

Switzerland

Industry

Biotechnology

Market Cap

192.4m USD

Dividend Yield

0%

Description

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

Contact

VAUD
Epalinges
Biopole, route de la Corniche 3B
+41216530200.0
adctherapeutics.com

IPO

-

Employees

312

Officers

CEO & Director
Dr. Ameet Mallik M.B.A., M.S.
Chief Financial Officer
Mr. Jose I. Carmona M.B.A.
Chief Medical Officer
Dr. Mohamed Zaki M.D., Ph.D.
Corporate Controller & Chief Accounting Officer
Ms. Lisa Michelle Kallebo
Chief Technical Operations Officer
Dr. Michael Mulkerrin Ph.D.
Chief Scientific Officer
Dr. Patrick van Berkel Ph.D.
Show More
Investor Relations Officer
Amanda Hamilton
Secretary & Chief Legal Officer
Mr. Peter J. Graham Esq.
Vice President of Investor Relations & Corporate Communications
Ms. Eugenia Litz
Senior VP & Chief People Officer
Ms. Kimberly Pope
Show Less

See Also

Discover More
What is the Intrinsic Value of one ADCT stock?

The intrinsic value of one ADCT stock under the Base Case scenario is 5.3 USD.

Is ADCT stock undervalued or overvalued?

Compared to the current market price of 1.99 USD, ADC Therapeutics SA is Undervalued by 62%.

Back to Top